Tuesday, June 26, 2012

Info 563 Case Reflection: Procter and Gamble


Before deciding to move forward with Web-Enabled EDC, I would like to share an article about a famous corporation that failed to see the future’s technology.


Quotes from the article:

-          Kodak did not fail because it missed the digital age. It actually invented the first digital camera in 1975. However, instead of marketing the new technology, the company held back for fear of hurting its lucrative film business, even after digital products were reshaping the market.

-          Unfortunately, the company had the nearsighted view that it was in the film business instead of the story telling business, and it believed that it could protect its massive share of market with its marketing. Kodak thought that its new digital technology would cannibalize its film business. Sony and Canon saw an opening and charged ahead with their digital cameras. When Kodak decided to get in the game it was too late. The company saw its market share decline, as digital imaging became dominant.

-          This blind faith in marketing’s ability to overcome the threat from the new technology proved fatal. Kodak failed to adapt to a new marketplace and new consumer attitudes.

Even though the Kodak situation is not 100% related to P&G’s Case study, it shows the long-term benefits that P&G may gain from the Web-Enabled EDC. D’Alonzo feels confident about recommending a shift toward the technology as the default standard for the company’s future trials based on the results of the pilot trials and his own knowledge of how Web-enabled EDC speeds up the process of trial management. Although D’Alonzo is worried about other pharmaceutical companies’ slowness in adopting the Web-enabled EDC, he still feels correct about EDC.

I believe that D’Alonzo is correct. Even though the costs and benefits of the technology Web-enabled EDC is uncertain, I believe that this technology would benefit P&G in long term, or at least, it will put them on a higher standard compared to other pharmaceutical companies.

No comments:

Post a Comment